PharVision Advisers’s AvePoint AVPT Stock Holding History

PharVision Advisers’s Portfolio AVPT Stock Details AVPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,733	Closed	-$102K	–	70
2026 Q1	$102K	Sell	10,733 -7,055	-40%	-$79.5K	1.04%	46
2025 Q4	$247K	Sell	17,788 -2,742	-13%	-$37.9K	0.13%	399
2025 Q3	$308K	Buy	+20,530	New	+$345K	0.17%	212
2025 Q2	–	Sell	-11,657	Closed	-$168K	–	277
2025 Q1	$168K	Buy	+11,657	New	+$196K	0.23%	219

Other funds holding AVPT

Anchor @ 65 Singapore $355M AUM 27.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCM

Parsifal Capital Management Greenwich, Connecticut $826M AUM 47.87% 1-Year Est. Return

PharVision Advisers's AVPT Position: Q2 2026 in Review

PharVision Advisers sold out of AvePoint (AVPT) in Q2 2026, closing a stake of 10,733 shares — an estimated $102K sold.

PharVision Advisers first reported a position in AVPT in Q1 2025 and held it in 4 quarters. The position peaked at $308K in Q3 2025. 253 funds tracked by Wall St. Rank hold AVPT as of Q2 2026.

PharVision Advisers reported no remaining AvePoint position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 10,733 AvePoint shares in Q2 2026, an estimated $102K.
PharVision Advisers first reported a position in AvePoint in Q1 2025 and held it in 4 quarters.
PharVision Advisers's AvePoint position peaked at $308K in Q3 2025.
253 funds tracked by Wall St. Rank held AvePoint as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.